Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | METAP1 | P53582 | 2/20 | 0.50 |
| ▸ | MAOB | P27338 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA4 | P22748 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.46 |
| ▸ | PRNP | P04156 | 1/20 | 0.46 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL630002 | 0.87 | SMN1; SMN2 (0.66) | SMN1; SMN2METAP1ALDH1A1CYP3A4THRB | |
| SCHEMBL14409344 | 0.84 | HTR2A (0.53) | SMN1; SMN2METAP1MAOBALDH1A1ACHE | |
| SCHEMBL2351080 | 0.83 | METAP1 (0.53) | SMN1; SMN2METAP1MAOBALDH1A1CYP3A4 | |
| SCHEMBL30176810 | 0.83 | METAP1 (0.53) | SMN1; SMN2METAP1MAOBALDH1A1CYP3A4 | |
| Hydrochloric Acid SCHEMBL7205753 | 0.82 | SMN1; SMN2 (0.47) | SMN1; SMN2METAP1MAOBALDH1A1CYP3A4 | |
| SCHEMBL8779124 | 0.81 | HTR2A (0.51) | SMN1; SMN2METAP1MAOBALDH1A1ACHE | |
| SCHEMBL345330 | 0.80 | SMN1; SMN2 (0.81) | SMN1; SMN2METAP1MAOBALDH1A1ACHE | |
| SCHEMBL13004977 | 0.79 | SIGMAR1 (0.62) | SMN1; SMN2METAP1MAOBCYP19A1 | |
| SCHEMBL6799152 | 0.79 | METAP1 (0.49) | SMN1; SMN2METAP1MAOBALDH1A1ACHE | |
| SCHEMBL13254665 | 0.79 | SMN1; SMN2 (0.60) | SMN1; SMN2METAP1MAOBMAPK1ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8436035-B2 | Organic compounds | NOVARTIS AG (CH) | 2013-05-07 | — | — | US | disclosed |
| US-8436035-B2 | Organic compounds | NOVARTIS AG (CH) | 2013-05-07 | — | — | US | disclosed |
| EP-2213668-A2 | Imidazoles as aldosterone synthase inhibitors | Novartis AG (CH) | 2010-08-04 | — | — | EP | disclosed |
| US-20100048562-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-02-25 | — | — | US | disclosed |
| US-20100048562-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-02-25 | — | — | US | disclosed |
| US-20100048562-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-02-25 | — | — | US | disclosed |
| EP-2094680-A2 | IMIDAZOLES AS ALDOSTERONE SYNTHASE INHIBITORS | Novartis AG (CH) | 2009-09-02 | — | — | EP | disclosed |
| WO-2008076336-A2 | IMIDAZOLES AS ALDOSTERONE SYNTHASE INHIBITORS | NOVARTIS AG (CH) | 2008-06-26 | — | — | WO | disclosed |
| WO-2008076336-A2 | IMIDAZOLES AS ALDOSTERONE SYNTHASE INHIBITORS | NOVARTIS AG (CH) | 2008-06-26 | — | — | WO | disclosed |
| EP-1869041-A1 | TETRAHYDRO-PYRIDOAZEPIN-8-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA | Warner-Lambert Company LLC (US) | 2007-12-26 | — | — | EP | disclosed |
| US-7196076-B2 | Androgen receptor modulators and methods of use thereof | MERCK & CO., INC. (US) | 2007-03-27 | — | — | US | disclosed |
| US-7196076-B2 | Androgen receptor modulators and methods of use thereof | MERCK & CO., INC. (US) | 2007-03-27 | — | — | US | disclosed |
| US-20060234997-A1 | Tetrahydro-pyridoazepin-8-ones and related compounds for the treatment of schizophrenia | WARNER-LAMBERT COMPANY LLC | 2006-10-19 | — | — | US | disclosed |
| WO-2006103559-A1 | TETRAHYDRO-PYRIDOAZEPIN-8-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA | WARNER-LAMBERT COMPANY LLC (US) | 2006-10-05 | — | — | WO | disclosed |
| US-20040198717-A1 | Androgen receptor modulators and methods of use thereof | MERCK SHARP & DOHME CORP. | 2004-10-07 | — | — | US | disclosed |
| US-6235789-B1 | GLANDULAR DISORDERS; SLEEP DISORDERS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-05-22 | — | — | US | disclosed |
| EP-0781271-A1 | BENZOCYCLOALKENE COMPOUNDS, THEIR PRODUCTION AND USE | Takeda Chemical Industries, Ltd. (JP) | 1997-07-02 | — | — | EP | disclosed |
| WO-1996008466-A1 | BENZOCYCLOALKENE COMPOUNDS, THEIR PRODUCTION AND USE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1996-03-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060234997-A1 | Tetrahydro-pyridoazepin-8-ones and related compounds for the treatment of schizophrenia | PTGDR, GRIN2A, PTGDR2 | SMN1; SMN2 3061/4885METAP1 3687/4885MAOB 13/4885 |
| US-20100048562-A1 | ORGANIC COMPOUNDS | CYP11B1, HSD11B1, CYP17A1 | SMN1; SMN2 4471/4885METAP1 1959/4885MAOB 98/4885 |
| US-20040198717-A1 | Androgen receptor modulators and methods of use thereof | AR, SHBG, FSHR | SMN1; SMN2 1408/4885METAP1 3573/4885MAOB 3975/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.